Summary
The collaboration is set to overcome bone and joint disorders with biocompatible bone regeneration
The two bodies have signed a technology licensing agreement as a part of the MoU.
Indian Institute of Technology (IIT) Kanpur has collaborated with Ortho Regenics Private Limited in a bid to bridge the gap between technology and medical disciplines. A Memorandum of Understanding (MoU) signed between the two entities will help Ortho Regenics Private Limited use the bone regeneration technology developed at IIT Kanpur.
As a part of the MoU, a technology licensing agreement was signed between the two parties on March 28. Ashok Kumar and Arun Kumar Teotia from the department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur have developed this pioneering technology.
Along with Kumar, other members of IIT Kanpur present at the MoU signing included deputy director and BSBE professor S Ganesh; Amitabha Bandyopadhyay, professor-in-charge (PIC), Innovation & Incubation; and Ankush Sharma, Co-PIC, Innovation & Incubation. Ortho Regenics director Gopal Pande and licensee and director Sudhir Reddy were also present for the signing. The two bodies have recognised that the objective of the collaboration is to alleviate bone and joint disorders.
IIT Kanpur director Abhay Karandikar said, “Healthcare is a sector that is inherently associated with the growth of technology. We have been striving to bring both disciplines closer to scale new highs in healthcare innovation and development. I am delighted about this development with Ortho Regenics, which would bring a paradigm shift in bone regeneration in humans and would be a boon for the ones suffering bone or joint disorders.”
There are existing remedies for bone regeneration, yet they pose the risk of infection and immune-related complications. The IIT Kanpur technology uses a collagen-nano-hydroxyapatite composite macroporous gel that has potential application in the reconstruction of irregular bone defects and dental applications. The technology is a carrier that delivers bone active biomolecules to the implant site directly. The new material is biodegradable and has bone healing (osteoinductive) and bone regenerative (osteopromotive) properties.
The novel material used is biocompatible, which results in improved cell material integration with osteoblast cells that are responsible for bone mineralisation. This improves the mechanical strength and interaction between the solvent and polymer network.
The functionalized porous composite scaffolds have the potential to act as fillers in large bone defects. They can also be used to overcome autograft limitations by acting as a bone substitute.
Last updated on 31 Mar 2022
